GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » Return-on-Tangible-Equity

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Return-on-Tangible-Equity : 18.92% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized net income for the quarter that ended in Mar. 2024 was E£228 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's average shareholder tangible equity for the quarter that ended in Mar. 2024 was E£1,205 Mil. Therefore, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 18.92%.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity or its related term are showing as below:

CAI:RMDA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.57   Med: 20.35   Max: 34.7
Current: 20.65

During the past 6 years, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's highest Return-on-Tangible-Equity was 34.70%. The lowest was 11.57%. And the median was 20.35%.

CAI:RMDA's Return-on-Tangible-Equity is ranked better than
81.9% of 939 companies
in the Drug Manufacturers industry
Industry Median: 6.33 vs CAI:RMDA: 20.65

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Return-on-Tangible-Equity Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Return-on-Tangible-Equity Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial 12.30 11.57 18.77 24.33 21.92

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.18 18.12 28.40 18.46 18.92

Competitive Comparison of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity falls into.



Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Return-on-Tangible-Equity Calculation

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=244.859/( (1061.019+1173.291 )/ 2 )
=244.859/1117.155
=21.92 %

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=228.036/( (1173.291+1237.297)/ 2 )
=228.036/1205.294
=18.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. It is engaged in the manufacture and sale of branded generic pharmaceutical products nutraceuticals, cosmeceuticals, food supplements, medical devices, and veterinary products. The firm is engaged in therapeutic areas namely systemic anti-infectives, alimentary tract and metabolism, genitourinary system and sex hormones, cardiovascular system, nervous system, and blood and blood-forming organs.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Headlines

No Headlines